OBJECTIVE: The goal of this study was to ascertain whether neuropeptide Y (NPY) is required in mice for the development of obesity induced by a high-fat diet (HFD), chemical lesions of the hypothalamus caused by monosodium glutamate (MSG) or gold thioglucose (GTG), impaired brown adipose tissue (BAT) due to a diphtheria toxin transgene driven by the uncoupling protein 1 promoter (UCP-DTA) or the lethal yellow agouti mutation (A y ). BACKGROUND: The obesity syndrome of the leptin-de®cient (ob/ob) mouse can be partially reversed by the genetic removal of NPY. In the murine models of obesity examined in this study, the animals become obese despite increased serum leptin levels, indicating that they are resistant to the weight-limiting actions of leptin. The role of NPY in these obesity models with elevated leptin levels is unknown. EXPERIMENTAL DESIGN: Mice lacking NPY due to genetic disruption of the gene and wildtype littermates were made obese by allowing them access to a highly palatable HFD, by treatment with MSG, or GTG, or by inheriting the dominant UCP-DTA or A y alleles. Food consumption, body weight and dissectable fat pad weights were measured and compared to values obtained from non-obese littermates. RESULTS: In each model of obesity tested, NPY-de®cient mice achieved the same food intake, body weight and fat content as wildtype littermates. CONCLUSION: NPY is not necessary for the progressive development of obesity exhibited by multiple murine models with leptin resistance.
Introduction
Neuropeptide Y (NPY) is a 36 amino acid peptide released by neurones throughout the central and peripheral nervous system of mammals.
1,2 Within the hypothalamus, neuronal cell bodies in the arcuate nucleus produce NPY and send projections to various other hypothalamic nuclei, including the paraventricular nucleus (PVN) and ventromedial hypothalamus (VMH). 3 These regions of the brain are thought to regulate adiposity by affecting appetite and metabolism. 4, 5 When laboratory animals are fasted, the expression of arcuate NPY and its release in the PVN and VMH is greatly increased. 6, 7 In addition, intracerebroventricular administration of NPY into the brain stimulates robust feeding and reduces core body temperature.
8 ±10 Furthermore, prolonged administration of NPY promotes accumulation of adipose tissue and ultimately leads to an obese state. 11±13 Based on this evidence, endogenous hypothalamic NPY is thought to be an important stimulator of energy balance.
14,15 However, we have recently inactivated the NPY gene in mice by homologous recombination and discovered that these NPY-de®cient mice exhibit normal feeding and adiposity under standard vivarium conditions and in response to starvation. 16 Mutant obaob mice are morbidly obese because of their inability to produce leptin, a peptide hormone secreted by adipocytes which acts centrally via receptors in the hypothalamus to reduce food consumption and stimulate energy expenditure. 17, 18 Lacking this satiety signal, obaob mice have an increased rate of food consumption and a low metabolic rate. 19 In addition, NPY is greatly elevated in the hypothalamus of these animals. 20, 21 Administration of leptin to obaob mice decreases NPY levels, reduces food intake, speeds energy expenditure and rapidly reduces their obesity. 22À24 To determine if the elevation of hypothalamic NPY contributes to the obesity of obaob mice, we recently bred the ob mutation onto the NPYde®cient background. Mice lacking both leptin and NPY consume less food, expend more energy, weigh less and have about 50% less adipose tissue than obaob mice with intact NPY genes. 25 The loss of NPY does not, however, completely ameliorate the obesity syndrome of the obaob mice. 25 The results of this genetic cross prove that NPY is one factor that mediates the increase in energy stores in response to leptin's absence.
In contrast to obaob mice, multiple murine models of obesity exist in which leptin levels are actually elevated, an indication that the animals no longer respond to leptin's obesity-preventing signal. 26Y27 For example, mice become obese despite rising leptin levels when fed a highly palatable, energy-dense diet with a high content of fat and sucrose. 28Y29 Obesity resulting from hypothalamic lesions induced by the toxins monosodium glutamate (MSG) or gold thioglucose (GTG) also result in elevated leptin. Subcutaneous (sc) administration of MSG to neonates produces cell loss speci®cally in the arcuate nucleus, 30 a region of the hypothalamus containing signi®cant levels of leptin receptors as well as NPY-expressing cells. 31, 32 The resulting obesity is accompanied by reductions in many pituitary hormones (such as growth hormone) and a stunted somatic growth rate. 33 GTG injected intraperitoneally (ip) into adult mice, causes neuronal loss in the VMH (a satiety center) 4 and thereby induces a period of robust overeating. 34 There are also genetic lines of obese mice characterized by high leptin levels. Mice with impaired function of brown adipose tissue (BAT) due to the BAT-speci®c expression of diphtheria toxin, become obese because of decreased energy expenditure. 35 Mice carrying the A y mutation have a yellow coat and late-onset obesity resulting from ectopic expression of the agouti signalling protein (ASP). 36Y37 Their obesity is thought to be induced by the antagonistic action of ASP on the brain-speci®c melanocortin 4 receptor (MC4R). 38, 39 To determine if NPY is critical for the development of obesity when leptin is intact, we tested the NPY-de®cient mice in each of the models of obesity described above.
Methods

General procedure
The mice used in this study were C57B1aJ6 strain Â 129Sv strain F 2 and F 3 -hybrids unless otherwise noted. Genotyping for NPY was performed by duplicate dot hybridizations of tail DNA with DNA probes corresponding to the lacZ gene and the region deleted from the NPY locus as previously described. 16 Mice were housed in a 22
C vivarium on a 12 h light cycle. Unless otherwise noted, they were allowed free access to water and a diet consisting of 4% crude fat [Rodent Diet (W) 8604, Harlan Teklad, USA]. For food consumption measurements, mice were housed 1 ± 3 to a cage and the amount of food consumed from a pre-weighed aliquot in three consecutive 5 d periods was measured.
Mice were then killed by CO 2 inhalation, after which total body weight and body length (nose to anus) were measured. Four sets of fat pads (inguinal, reproductive, retroperitoneal and scapular) were also dissected and weighed. All data were calculated by comparing the food intake, body weight and dissected adipose tissue weight of each obese mouse, to the mean values obtained from the respective non-obese control group. Statistically signi®cant differences were determined using the Student's t-test.
High-fat diet (HFD)
The HFD (Research Diets, Inc., USA) consists of fat (58 kJ%) primarily in the form of hydrogenated coconut oil and carbohydrate (26 kJ%) supplied by sucrose. This diet also contained all essential vitamins and minerals. Male mice (approximately 8 weeks old) were allowed ad libitum access to the diet for approximately 16 weeks.
Chemical lesions
MSG (Sigma, St Louis, MO) was administered daily to mice on postnatal days 1 ± 7 at a dose of 2 gakg sc. This effectively produced an obesity phenotype in all animals. GTG (Sigma, St Louis, MO) was given to adult female mice (approximately 12 ± 16 weeks old) as a single ip injection of 600 mgakg. This treatment resulted in some mortality 4 d after treatment (7 of 26 NPY a mice or 27%, and 9 of 26 NPY 7a7 mice or 35%), and produced obesity in only a fraction of the mice (12 of 26 NPY a or 46%, and 11 of 26 NPY 7a7 mice or 42%). The results of this dose are shown in Figure 3 . Previously, GTG (Fluka, Buchs, Switzerland) had been tested at a dose of 800 mgakg. This treatment produced greater mortality in the NPYde®cient mice (8 of 27 NPY a mice, or 30%, vs 13 of 21 NPY 7a7 mice, or 62%). The different response of the NPY-de®cient mice was probably not due to the greater dose of GTG, but due instead to differences in fabrication (Sigma vs Fluka). Treatment with 600 mgakg of GTG from Fluka did not produce a signi®cant increase in body weight or food intake of our mice.
Genetic crosses
Male A y (genotype A y aa) mice (C57B1aJ6 strain, Jackson Labs, Bar Harbor, USA) were bred with female aaa NPY 7a7 mice (C57B1aJ6 Â 129Sv F 2 -hybrids) to produce a breeding colony of A y aa NPY a7 mice mated with aaa NPY a7 mice. The A y mutation is dominant and homozygous lethal, 40 so A y aa offspring were identi®ed by their phenotypic yellow coat. Male mice (FVBaN strain) carrying UCP-DTA transgene 35 were kindly provided by Jeffrey S. Flier (Harvard Medical School) and bred with NPY 7a7 females (C57B1aJ6 Â 129Sv F 2 -hybrids). Offspring which inherited the transgene were detected by DNA dot hybridization using a DTA probe. They were bred with the non-carriers from this ®rst cross to generate the mice used in this study.
Results
The effect of NPY-de®ciency on the food intake, body weight and length, and adiposity of each murine obesity model is summarized in Table 1 . There were no NPY and murine obesity models G Hollopeter et al statistical differences in food intake, body weight or adipose tissue weight between the NPY-de®cient and wild-type animals used as non-obese controls for each model.
Male mice were placed on a HFD which has been shown to induce obesity, diabetes and fatty livers in laboratory rodents. 28, 29 Both the NPY-de®cient and normal mice (data from NPY a and NPY a7 mice were grouped because they were equivalent) consumed slightly fewer grams of this HFD when compared to the daily food intake of mice fed a normal diet containing 4% calories from crude fat (Figure 1 ), because the fatty diet is more energy dense (5.56 kcalag) than the normal diet (3.93 kcalag). Thus, the energy intake of the mice on the HFD was actually greater (Table 1) . After four months on this diet, the body weights of NPY knockout mice were only slightly greater than those of NPY /,a7 mice which consumed the same diet, or mice which ate normal chow (Figure 1 ). However, upon weighing four sets of dissectable fat pads, it was apparent that the mice fed the HFD had more adipose tissue than mice fed the control diet, but that NPY-de®cient animals became as obese as normal mice (Figure 1 ). The actual increase in the fat pad weights of the mice fed the HFD was only about 1 g, which was too small to represent a signi®cant increase in overall body weight (Table 1) .
To determine if NPY plays a role in MSG-induced obesity, NPY-de®cient and wildtype neonatal mice were treated with MSG. When the mice were six months old they consumed less food than untreated animals of the same age (Figure 2 ), but weighed more ( Figure 2 ). The body length of MSG-treated mice was also reduced compared to that of untreated mice (Table 1) . Combined fat depots of MSG-treated animals weighed much more than those of untreated mice, but the NPY-de®cient mice became just as obese as controls (Figure 2) .
To determine if NPY is required for the obesity produced by GTG treatment, four-month-old NPY 7a7 females and their wildtype littermates were given a single ip injection of GTG and monitored for two months. This treatment produced obesity (a weight gain b25% of initial body weight) in 46% of control and 42% of mutant mice (see Methods). The criteria of 25% weight gain was chosen, because this eliminated animals exhibiting normal weight gain and this threshold was similar to that Figure 1 Effect of neuropeptide Y (NPY) de®ciency on food consumption, body weight and adiposity, following diet-induced obesity. Two-month-old male mice were placed on a high fat, high-sucrose diet for four months. 28 Daily food intake of mice eating the high fat diet (HFD) was slightly less than that of animals consuming standard chow. At the end of the study, the treated mice had body weights similar to control mice. However, after consuming HFD, the mice had an increased fat content (*P`0.05). Data represent the mean AE s.e.m. for n 10 ± 13 male mice. There were no signi®cant differences in food intake, body weight or fat pad weight between NPY 7/7 and wildtype mice after consuming the HFD. For actual values, see Table 1 .
NPY and murine obesity models G Hollopeter et al used in previous studies. 26, 41 After two months, food intake was elevated in the obese GTG-treated mice when compared to untreated control mice, regardless of their NPY genotype (Figure 3) . The mean body weight of NPY-de®cient and control mice after GTG treatment was also similarly increased (Figure 3) , as was their body length ( Table 1) . Dissection of fat pads revealed that NPY-de®cient mice treated with GTG became just as obese as GTG-treated wildtype animals; both groups were much more obese than untreated controls (Figure 3) .
Mice carrying the UCP-DTA transgene 35 were bred onto the NPY-de®cient background to determine if NPY promotes the obesity produced by the transgene. UCP-DTA mice and their littermate controls were maintained for seven months during which time their body weights were monitored. When the animals became obviously obese at about six months of age, their food consumption was measured. There was no effect of the UCP-DTA transgene on food consumption in either the wildtype or NPY-de®cient background (Figure 4 ). Following this, the mice were killed and the mass of their fat depots was determined. As shown in Figure 4 , the UCP-DTA mice weighed more and had an increased fat content when compared to non-transgenic mice. However, the loss of NPY did not signi®cantly alter the obesity produced by the transgene. Figure 2 Effect of neuropeptide Y (NPY) de®ciency on food consumption, body weight and adiposity of monosodium glutamate (MSG)-treated mice. Six-month-old male mice treated neonatally with MSG consumed less food than untreated controls (*P`0.05). However, MSG-treated mice had a greater body weight (*P`0.05) and contained more fat (**P`0.001) than control mice. Data represent the mean AE s.e.m. for n 7 ± 13 animals. There were no signi®cant differences in food intake, body weight, or fat pad weight between NPY-de®cient and wildtype mice following MSG treatment. For actual values, see Table 1 . Figure 3 Effect of neuropeptide Y (NPY) de®ciency on food consumption, body weight and adiposity of gold thioglucose (GTG)-treated mice. Animals given a single injection of GTG, consumed more food than control mice (*P`0.05). Two months after treatment, GTG-treated mice weighed more than untreated mice **P`0.001). The GTG-treated mice also had much larger fat pads when compared to non-obese controls **P`0.001). Data represents the mean AE s.e.m. for n 11 ± 18 female mice. There were no signi®cant differences in food intake, body weight or fat pad weight between NPY-de®cient and wildtype mice following GTG treatment (see Methods). For actual values, see Table 1 . Figure 4 Effect of neuropeptide Y (NPY) de®ciency on food consumption, body weight and adiposity of UCP-DTA mice. The UCP-DTA transgene was bred onto the NPY 7/7 background and the mice were maintained for seven months. During this time, the mice carrying the transgene, consumed the same amount of food as mice lacking the transgene. Seven-month-old UCP-DTA mice had an increased body weight (**P`0.001). At this age, UCP-DTA mice also had an elevated fat content (**P`0.001). Data represent the mean AE s.e.m. for n 11 ± 31 male mice. There were no signi®cant differences in food intake, body weight or fat pad weight between NPY-de®cient and wildtype UCP-DTA mice.
For actual values, see Table 1 . Figure 5 Effect of neuropeptide Y (NPY) de®ciency on food consumption, body weight and adiposity of A y mice. The A y mice and their littermates were maintained under standard vivarium conditions for eight months. Measurement of food intake revealed that the NPY-de®cient A y mice overate to the same extent as NPY / A y mice (*P`0.05). The A y mice also had a greater body mass (**P`0.001) and contained more adipose tissue (**P`0.001) when compared to littermates. Data represent the mean AE s.e.m. for n 9 ± 15 male mice. There were no signi®cant differences in food intake, body weight or fat pad weight between NPY-de®cient and wildtype A y mice. For actual values, see Table 1 .
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To test if NPY is responsible for the obesity of A y mice, the A y mutation was bred onto the NPY-de®-cient background and the mice were maintained for seven months. During this time their food consumption and body weights were monitored. Seven-monthold A y NPY 7a7 and A y NPY a mice consumed slightly more food on a daily basis than littermates without the A y allele (a/a) ( Figure 5 ). The mean body weight of A y mice was also greater than aaa mice, regardless of their NPY genotype ( Figure 5 ). At eight months of age, the mice were killed and their fat pads weighed. Compared to controls, the A y mice had a much greater fat content, regardless of their NPY status ( Figure 5) . A y mice were also longer than aaa mice, independent of NPY ( Table 1) .
Discussion
This study was undertaken to determine if NPY is required for the development of diet-, chemical-or genetic-induced obesity models, characterized by elevated levels of leptin. The absence of NPY, due to genetic ablation, did not alter the food intake, body weight or fat content of each murine model of obesity tested. In contrast to these ®ndings, we previously demonstrated that the removal of NPY partially reversed the obesity phenotype associated with leptin-de®cient, obaob mice. 25 Why did the loss of NPY not likewise attenuate the adiposity of the murine models tested in this study?
Unlike the obaob mouse, there does not seem to be a clearly de®ned up-regulation of hypothalamic NPY associated with the obesity models tested in this study. For example, the obesity induced by UCP-DTA does not alter the expression of arcuate NPY (J. Flier, personal communication, 1996) . It is also not clear whether a HFD increases or decreases NPY levels in the brain because both situations have been observed. 42, 43 The same is true for GTG-induced lesions of the VMH.
44 ± 46 Moreover, MSG treatment actually destroys the majority of the NPY-producing neurones in the arcuate nucleus, thereby reducing hypothalamic NPY content. 47, 48 One exception, however, has been noted in A y mice where NPY mRNA becomes elevated in the dorsal medial hypothalamus (DMH), 49 but not in the arcuate nucleus. It seems unlikely that this increase in NPY is directly responsible for the obesity of these animals, because the change in NPY expression occurs after the mice become quite obese and the DMH is not thought to regulate body composition. 49 Thus, it seems that NPY is not required for obesity in models where the expression of NPY in the arcuate nucleus is not greatly elevated.
The robust up-regulation of NPY noted in the hypothalamus of the obaob mouse, but not in the other murine models we tested, is presumably due to differences in leptin signalling. The obaob mouse is characterized by a genetic absence of leptin, which removes an inhibitor of NPY transcription in the arcuate nucleus. This elevation of NPY contributes to the hyperphagia and hypometabolism of the obaob model. 25 In the other murine models of obesity that we tested, the leptin gene is intact and the serum levels of leptin actually increase with adiposity. 26, 27 Thus, even though these obese mice resist leptin's action at some level, the leptin signal may be suf®cient to keep the transcription of NPY in check and prevent it from contributing to the obesity of these models.
The obesity resulting from the ob mutation is an extreme form of obesity associated with a voracious appetite in conjunction with hypoactivity and hypometabolism. 19 These robust phenotypes were only partially reduced by the removal of NPY, 25 so it is easy to imagine that loss of NPY in the lesser forms of murine obesity tested here, might produce small, undetectable changes. However, NPY-de®ciency did not even produce a trend toward reduced fat content in any of these murine models. Therefore, we conclude that NPY is not required for the development of obesity in the diet-induced, chemical-induced, or genetic-induced obesity models examined in this study. It is possible that a congenital lack of NPY is compensated for by other neuromodulators that can in¯uence appetite and body weight. This may explain why the NPY-de®cient mice display normal food intake and adiposity under ad libitum feeding conditions and in response to a 2 d fast. We have been examining this possibility in several ways.
We have shown that corticosterone, thyroid hormone and leptin levels are normal in NPY 7a7 mice and they all change signi®cantly in response to a 2 d fast, but there is no difference in the changes in NPY a and NPY 7a7 mice. 50 We have also examined the response of NPY 7a7 mice to several hypothalamic modulators of feeding including, corticotrophin releasing factor, a melanocortin receptor agonist (MTII), 51 dexfen¯uramine (a drug that potentiates serotonin action), galanin, noradrenaline as well as NPY itself, and found no differences between NPY a and NPY 7a7 mice (G. Hollopeter et al, in press, 1998. The same conclusion is being reached for agouti related peptide, an endogenous regulator of melanocortin receptors that is produced by NPY neurones in the arcuate and has the same effect on feeding as NPY (D. Marsh et al, unpublished observations, 1998). 52, 53 Furthermore, mice lacking the NPY-Y5 receptor, the so-called`NPY feeding receptor,' have normal growth, feeding behavior and they respond to fasting normally (D. Marsh et al, unpublished observation, 1998). These results, along with the fact that antibodies that cross-react with both NPY and peptide YY do not detect any immunoreactivity in NPY 7a7 mice, 16 argue that compensation by other members of the NPY family is unlikely.
Although it is not possible to de®nitively rule out compensation, the lack of evidence leads us to suggest NPY and murine obesity models G Hollopeter et al that NPY is not involved in regulation of feeding, except under extreme conditions. Perhaps NPY only in¯uences feeding when it is induced to high levels, as occurs in mice that cannot make or respond to leptin, 54 or when NPY is delivered at high doses pharmacologically. 10 If leptin de®ciency is the prime mediator of NPY induction in the arcuate nucleus and NPY produced by this nucleus is primarily involved in feeding, then the fact that all of the obesity models tested here have elevated leptin levels, could account for the lack of effects of NPY-de®ciency.
